Muscular dystrophy is mainly considered to be related to abnormalities in the conduction of neuromuscular junction transmitters. The clinical survival period is 2-10 years, and some patients are considered to have a shorter survival period due to their more rapid disease, some of them do not even exceed six months. There is no clear cause for the formation of muscular atrophy, some patients are due to genetic factors, and it may also be due to inflammation of the autoimmune system. If muscular dystrophy exists it is recommended to apply rehabilitation and physiotherapy drug therapy under the guidance of a physician to integrate the treatment and prolong the patient’s survival self-care and life expectancy. In the later stages of the disease there may be respiratory difficulties, requiring ventilators for assisted breathing and passive limb rehabilitation training while bedridden.